Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 18, 1998

View Archived Issues

L-Glutamine therapy beneficial for sickle cell anemia

TR1, new member of the TNFR superfamily and target for treating metabolic bone diseases

PKA I may be a valid target for immunomodulation in the HIV-infected patient

Bromocriptine reduces prolactin levels in patients with androgen-independent prostate cancer

Potent anti-HSV-1 activity demonstrated with BILD-1633-SE in vivo

Matrix granted Japanese patent; U.S. patent reissued

Anika: Q2 1998 highlights

Diacrin: Q2 1998 highlights

Salix: Q2 1998 highlights

Results support development of beta-L-Fd4C as an expanded-spectrum anti-HBV drug

Patent issued for Techniclone's Vascular Targeting Agent technology

Carotid artery intimal thickening prevented by TAS-301

New COX-2 inhibitors in early development at American Home

P&U discloses new distamycin derivatives with antitumor/antiviral efficacy

Two new series of PDE4 inhibitors reported by Byk Gulden

Otsuka adds new antidiabetic candidates to R&D pipeline

Insulin-sensitizing guanidine compounds discovered by Yamanouchi

Nonamine compounds inhibit monoamine transporters, contrary to prevailing beliefs

SynPhar's HLE inhibitors show unique potential in preventing lung injury

Ligand-Seragen merger process now completed

First filing for Novo Nordisk's fast-acting insulin analogue

The Medicines Company acquires clinical-stage antimigraine drug for development

SB-237376, a new antiarrhythmic agent with a dual mechanism of action and enhanced safety

Kissei studies beta-adrenergic drug for use in patients with urolithiasis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...